New combo therapy targets Hard-to-Treat esophageal cancer
NCT ID NCT04984733
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a two-step treatment for advanced esophageal cancer that has a specific genetic marker (MGMT deficiency) and has stopped responding to standard chemotherapy. First, patients took a daily oral chemotherapy drug (temozolomide) for three months. Then, they added an immunotherapy drug (nivolumab) either alone or with continued temozolomide. The study enrolled 13 adults and aimed to see if the combination could shrink tumors or control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
temozolomide and nivolumab
What this could lead to
If successful, this could point toward a new treatment option for a specific type of advanced esophageal cancer that has stopped responding to standard chemotherapy.
What could go wrong
This is a very small, early-phase trial with only 13 participants, so results may not apply to a broader population. The combination may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF ESOPHAGUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cambridge University Hospitals NHS Foundation Trust
Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom